Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Uterine Cervical Neoplasms × adavosertib × Clear all

Phase

Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uterine Cervical Neoplasms 1 Rhabdomyosarcoma 1 Pinealoma 1 Neuroectodermal Tumors, Primitive 1 Neuroblastoma 1 Neoplasms 1 Metastatic Pancreatic Adenocarcinoma 1 Medulloblastoma 1 Central Nervous System Neoplasms 1

Interventions

pembrolizumab 16 Cisplatin 9 Cyclophosphamide 8 Carboplatin 8 fludarabine 6 Paclitaxel 6 Bevacizumab 6 aldesleukin 5 Nivolumab 5 toripalimab 4 tisotumab vedotin 4 fludarabine phosphate 4 Radiotherapy 4 Interleukin-2 4 Brachytherapy 4 spartalizumab 3 Topotecan 3 Ipilimumab 3 Fulvestrant 3 Docetaxel 3 ferumoxtran-10 2 enzalutamide 2 durvalumab 2 balstilimab 2 Trastuzumab 2 Magnetic Resonance Spectroscopy 2 Injections 2 Gemcitabine 2 Celecoxib 2 Biopsy 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01076400 2023-09-18

MK-1775-008

Merck Sharp & Dohme LLC

Phase 1/2 Terminated

7 enrolled 6 charts

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡